Abstract
The rationale for the development of selective inhibitors of cyclooxygenase-2 (COX-2) was the proposal that this enzyme plays an important role in inflammation but does not contribute to the resistance of the gastrointestinal mucosa against injury. However, studies from several groups have established that both COX-1 and COX-2 have important functions in the maintenance of gastrointestinal mucosal integrity. Thus, in the normal rat stomach lesions only develop when both COX-1 and COX-2 are inhibited. On the other hand, in specific pathophysiological situations the isolated inhibition of either COX-1 or COX-2 without simultaneous suppression of the other COX isoenzyme is ulcerogenic. Furthermore, COX-2 plays an important role in the healing of gastric ulcers and inhibition of COX-2 delays ulcer healing. From these findings the initial concept that only inhibition of COX-1 interferes with gastrointestinal defense has to be re-evaluated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bombardier, C., Laine, L., Reicin, A., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N. Engl. J. Med. 343, 1520–1528.
Capdevila, J. H., Wei, S., Yan, J., et al. (1992). Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading, J. Biol. Chem. 267, 21720–21726.
Chandrasekharan, N. V., Dai, H., Roos, K. L., et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc. Natl. Acad. Sci. USA 99, 13926–13931.
Ehrlich, K., Plate, S., Stroff, T., et al. (1998). Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: role of cyclooxygenase-2, Am. J. Physiol. 274, G955–G964.
Ehrlich, K., Sicking, C., Respondek, M., et al. (2004). Interaction of cyclooxygenase isoenzymes, nitric oxide, and afferent neurons in gastric mucosal defense in rats, J. Pharmacol. Exp. Ther. 308, 277–283.
Gretzer, B., Ehrlich, K., Maricic, N., et al. (1998). Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach, Br. J. Pharmacol. 123, 927–935.
Gretzer, B., Maricic, N., Respondek, M., et al. (2001a). Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge, Br. J. Pharmacol. 132, 1565–1573.
Gretzer, B., Schuligoi, R. and Peskar, B. M. (2001b). Effect of dexamethasone on gastric mucosal integrity in rats treated with a COX-1 or COX-2 inhibitor, Gastroenterology 120, A151.
Hawkey, C. J. (1990). Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiple, but do they add up?, Br. Med. J. 300, 278–284.
Hawkey, C. J. and Hudson, N. (1994). Mucosal injury caused by drugs, chemicals and stress, in: Bockus Gastroenterology, Haubrich, W. S., Schaffner, F. and Berck, J. E. (Eds), pp. 656–699. W. B. Saunders, Philadelphia, PA.
Jackson, L. M. and Hawkey, C. J. (2000). COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages?, Drugs 59, 1207–1216.
Kargman, S., Charleson, S., Cartwright, M., et al. (1996). Characterization of Prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts, Gastroenterology 111, 445–454.
Kishimoto, Y., Wada, K., Nakamoto, K., et al. (1998). Levels of cyclooxygenase-1 and-2 mRNA expression at various stages of acute gastric injury induced by ischaemia-reperfusion in rats, Arch. Biochem. Biophys. 352, 153–157.
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., et al. (1991). TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue, J. Biol. Chem. 266, 12866–12872.
Langenbach, R., Morham, S. G., Tiano, H. F., et al. (1995). Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration, Cell 83, 483–492.
Lewis, R. A., Austen, K. F. and Soberman, R. J. (1990). Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases, N. Engl. J. Med. 323, 645–655.
Maricic, N., Ehrlich, K., Gretzer, B., et al. (1999). Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach, Br. J. Pharmacol. 128, 1659–1666.
Maricic, N., Ehrlich, K. H. and Peskar, B. M. (2001). Effect of cyclooxygenase-1 inhibitor SC-560 on mucosal damage during ischaemia-reperfusion in the rat stomach, Gastroenterology 120, A152.
Marnett, L. J. (1992). Aspirin and the potential role of prostaglandins in colon cancer, Cancer Res. 52, 5575–5589.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., et al. (1994). Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic, Proc. Natl. Acad. Sci. USA 91, 3228–3232.
Masferrer, J. L., Zweifel, B. S., Seibert, K., et al. (1990). Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice, J. Clin. Invest. 86, 1375–1379.
Mizuno, H., Sakamoto, C., Matsuda, K., et al. (1997). Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice, Gastroenterology 112, 387–397.
Morham, S. G., Langenbach, R., Loftin, C. D., et al. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse, Cell 83, 473–482.
O’Banion, M. K., Winn, V. D. and Young, D. A. (1992). cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase, Proc. Natl. Acad. Sci. USA 89, 4888–4892.
Peskar, B. M., Gretzer, B., Schuligoi, R., et al. (2001). Dexamethasone impairs gastric mucosal integrity in rats treated with a COX-1 but not with a COX-2 inhibitor, Z. Gastroenterol. 39, 1050.
Peskar, B. M., Sawka, N., Ehrlich, K., et al. (2003). Role of cyclooxygenase-1 and-2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection, J. Pharmacol. Exp. Ther. 305, 1233–1238.
Raz, A., Wyche, A. and Needleman, P. (1989). Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases, Proc. Natl. Acad. Sci. USA 86, 1657–1661.
Robert, A., Nezamis, J. E., Lancaster, C., et al. (1983). Mild irritants prevent gastric necrosis through “adaptive cytoprotection” mediated by prostaglandins, Am. J. Physiol. 245, G113–G121.
Schmassmann, A., Peskar, B. M., Stettler, C., et al. (1998). Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats, Br. J. Pharmacol. 123, 795–804.
Smith, W. L. and Marnett, L. J. (1991). Prostaglandin endoperoxide synthase: structure and catalysis, Biochim. Biophys. Acta 1083, 1–17.
Tanabe, T. and Tohnai, N. (2002). Cyclooxygenase isozymes and their gene structures and expression, Prostaglandins Other Lipid Mediat. 68–69, 95–114.
Tanaka, A., Araki, H., Komoike, Y., et al. (2001). Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs, J. Physiol. 95, 21–27.
Vane, J. R. and Botting, R. M. (1995). New insights into the mode of action of anti-inflammatory drugs, Inflamm. Res. 44, 1–10.
Wallace, J. L., McKnight, W., Reuter, B. K., et al. (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2, Gastroenterology 119, 706–714.
Wight, N. J., Gottesdiener, K., Garlick, N. M., et al. (2001). Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production, Gastroenterology 120, 867–873.
Yokota, A., Tanaka, A., Kubo, Y., et al. (2004). Dexamethasone produces damage in the stomach but not small intestine under inhibition of cyclooxygenase (COX)-1, Gastroenterology 126, A615.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peskar, B.M. Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. Inflammopharmacol 13, 15–26 (2005). https://doi.org/10.1163/156856005774423809
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1163/156856005774423809